In September 1960, Frances Oldham Kelsey arrived at the Food and Drug Administration for her first month on the job and was handed what looked like a routine assignment. A pharmaceutical company called William S. Merrell wanted FDA approval to market a sedative called Kevadon, already widely used across Europe under the name thalidomide.
Merrell expected a quick sign-off. The drug was already selling in over 20 countries.
Kelsey said no.
Something in the safety data bothered her. It was thin and inconsistent, relying heavily on anecdotal evidence rather than the rigorous clinical evidence she believed was necessary. Her supervisors received complaints.
Merrell's representatives called her and her bosses 50 separate times, crowded into her office, and labeled her a petty bureaucrat for holding up a clearly safe drug. She held her ground through every visit, every letter, and every phone call for 19 months.
By late 1961, the evidence from Europe had become undeniable. Thalidomide was causing catastrophic birth defects in thousands of babies, a condition called phocomelia in which limbs failed to develop properly. Around 100,000 children across Europe, Britain, Canada, and the Middle East were affected. Thousands of babies were stillborn. The drug was pulled from global markets.
In the United States, the only exposure came through sample packets Merrell had already distributed to doctors' offices before Kelsey's review concluded, affecting several hundred cases. The mass catastrophe seen elsewhere never happened.
On August 7, 1962, President John F. Kennedy awarded Kelsey the President's Award for Distinguished Federal Civilian Service, the highest civilian honor in the country. She was only the second woman to receive it.
Her refusal also directly triggered the 1962 Kefauver-Harris Amendment, which fundamentally reformed how drugs are approved in America, requiring companies to prove both safety and effectiveness before any drug reaches the public.
Frances Kelsey died in August 2015 at the age of 101.